Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Kimball AB, Jemec GBE, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG et al.
Lancet 2023; 401: 747-761.
This analysis of two identical trials included over one thousand patients. Secukinumab given fortnightly was more effective in both trials at reducing the signs of symptoms of hidradenitis than placebo (or Secukinumab every four weeks).
Comment: Effective, with good safety profile.
26 April 2023Read paper
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.